Despite the crucial role that the PD-1/PD-L1 pathway plays in limiting anti-tumor immune responses, there are no data exploring the potential influence of PD-1 polymorphisms on the treatment response to anti-PD-1 blockade. Here, CD274 is linked to neoplasm.